EP 204: Bringing cardiovascular genetics and biobank discoveries into the clinic with Samuli Ripatti

Value of the Information & Strength of the Argument

The value of the information is high, as it provides expert insights into the practical application of polygenic risk scores in clinical settings. Ripatti’s argumentation is well-structured, presenting a clear framework for clinical implementation and supporting it with specific examples from his research. He acknowledges limitations and statistical challenges, such as confounding by treatment, demonstrating a balanced and rigorous approach. The discussion is grounded in real-world data from FinnGen and published studies, enhancing its credibility.

The title accurately reflects the content, which focuses on translating cardiovascular genetics and biobank discoveries into clinical practice.

8/10

The content is an expert interview with a leading researcher in cardiovascular genetics and biobank science. The discussion is grounded in published research and real-world biobank data, with references to specific studies and data sources. The speaker demonstrates deep knowledge and provides nuanced perspectives on clinical implementation and statistical challenges.

• 00:00Intro to The Genetics Podcast
• 00:59Welcome to Samuli
• 01:48Samuli’s path from statistics to genetics at the beginning of a new era
• 03:09Remembering Leena Peltonen and the Human Genetics Summer School
• 05:46Samuli’s research in lipid and cardiovascular genetics and the power of collaboration
• 09:14Integrating polygenic risk scores into cardiovascular and breast cancer care
• 14:52Using medication history in FinnGen to uncover cardiometabolic genetics and predict treatment patterns
• 18:50The future of polygenic risk scores in predicting prognosis and guiding treatment
• 21:21The confounding effect of treatment in genetic studies
• 23:14Overview of FinnGen and its impact on genetics and drug discovery
• 27:04The next 5 years in proteomics and molecular profiling to move beyond associations
• 29:56Using polygenic risk scores in clinical trials
• 31:41Future directions, from refining phenotypes in large biobanks to piloting clinical applications of polygenic risk scores
• 34:04Scaling population biobanks versus deep phenotyping and why the future requires both
• 35:29Closing remarks

• Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases — Referenced in the description as a key publication discussed in the episode.
• Show notes document — Linked in the description as additional show notes.

• Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases — The study discussed in the episode, providing evidence for the utility of medication history in genetic research.